Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska
About Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Celgene
4
Biogen
1
Clinical Trials at Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska
During the past decade, Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 4 clinical trials were completed, i.e. on
average, 400% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 3 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
2012-09-18
2016-05-11
Completed
258
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
2013-08-01
2016-03-01
Completed
419
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
2013-12-03
2017-04-13
Completed
1,320
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
2014-12-03
2016-12-22
Completed
1,346
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
2015-10-16
2023-01-05
Completed
2,350
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska
According to Clinical.Site data, the most researched conditions in "Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska" are
"Multiple Sclerosis" (3 trials) and "Relapsing Multiple Sclerosis" (2 trials). Many other conditions were trialed in "Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska" in a lesser frequency.
Clinical Trials Intervention Types at Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska
Most popular intervention types in "Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska" are "Drug" (5 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Ozanimod" (3 trials), "Interferon beta-1a" (2 trials), "Placebo" (2 trials), "Avonex" (1 trials) and "BIIB033" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska
The vast majority of trials in "Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska" are
5 trials for "All" genders.
Clinical Trials Status at Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska
Currently, there are NaN active trials in "Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 5 completed trials in Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska, 0 "Phase 1"
clinical trials were conducted, 2 "Phase 2" clinical
trials and 4 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".